Skip to main content
. 2018 Aug 24;7(11):e1509821. doi: 10.1080/2162402X.2018.1509821

Figure 4.

Figure 4.

Functional activation of ALDH1-specific CD8+ cells in AGI-101H-treated melanoma patients upon vaccine administration. A. Representative dot plots presenting unstimulated, ALDH1A1 peptide stimulated, MAA peptides stimulated, and anti-CD3/anti-CD28 stimulated CD8+ T cells (from AGI-101H treated melanoma patient on the day of vaccine administration) stained with anti-CD107a and anti-IFN-γ. B. Representative dot plots presenting unstimulated, ALDH1A1 peptide stimulated, MAA peptides stimulated, and anti-CD3/anti-CD28 stimulated CD8+ T cells (from AGI-101H treated melanoma patient 6 days after vaccine administration) stained with anti-CD107a and anti-IFN-γ. C. Percentage of CD107a+IFN-γ+ cells in unstimulated, ALDH1A1 peptide stimulated, MAA peptides stimulated, and anti-CD3/anti-CD28 stimulated CD8+ T cells (from AGI-101H treated melanoma patient on the day of vaccine administration and 6 days later).